VolitionRx Targets French Reimbursement for Nu.Q® Cancer Assays by Q2 2026
Event summary
- VolitionRx preparing reimbursement submission for Nu.Q® Cancer assays in France, supported by Hospices Civils de Lyon (HCL).
- Submission under the 'Innovative Procedures Outside the Nomenclature' (RIHN) framework, with eligibility determination mandated to take no more than five months.
- HCL aims to introduce Nu.Q® into routine clinical practice for lung cancer management by Q4 2026.
- Approximately 50,000 new lung cancer diagnoses annually in France, with a five-year prevalence of 65,000 cases.
The big picture
VolitionRx's reimbursement submission for Nu.Q® Cancer assays marks a critical step in commercializing its epigenetic testing technology. Success in France could set a precedent for broader European adoption, leveraging the RIHN framework designed to support innovative medical procedures. The collaboration with HCL underscores the strategic importance of securing early clinical validation and reimbursement to drive market penetration in a high-prevalence lung cancer market.
What we're watching
- Regulatory Timelines
- Whether VolitionRx can secure reimbursement approval within the mandated five-month period under the RIHN framework.
- Commercial Expansion
- The pace at which VolitionRx can replicate this reimbursement strategy in other countries beyond France.
- Clinical Adoption
- How quickly HCL and other hospital networks integrate Nu.Q® into routine clinical practice for lung cancer management.
Related topics